Genprex (GNPX) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0001595248
Entity Registrant Name	Genprex, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38244
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772347
Entity Address, Address Line One	3300 Bee Cave Road, #650-227
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78746
City Area Code	512
Local Phone Number	537-7997
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GNPX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,020,304

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 30,053,021	$ 38,628,876
Prepaid expenses and other	847,802	511,348
Total current assets	30,900,823	39,140,224
Property and equipment, net	35,334	48,608
Other assets:
Security deposits	10,000	8,691
Supplies	2,952,917	3,022,403
Intellectual property, net	666,049	642,360
Total other assets	3,628,966	3,673,454
Total assets	34,565,123	42,862,286
Current liabilities:
Accounts payables	683,323	973,195
Other current liabilities	1,470,515	612,100
Total current liabilities	2,153,838	1,585,295
Stockholders’ equity:
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock $0.001 par value: 200,000,000 shares authorized; 47,898,351 and 47,874,708 shares issued and outstanding at June 30, 2022, and December 31, 2021, respectively	47,898	47,874
Additional paid-in capital	121,273,050	119,246,970
Accumulated deficit	(88,909,663)	(78,017,853)
Total stockholders’ equity	32,411,285	41,276,991
Total liabilities and stockholders’ equity	$ 34,565,123	$ 42,862,286

Condensed Balance Sheets (Cur_2

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	47,898,351	47,874,708
Common stock, shares outstanding (in shares)	47,898,351	47,874,708

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues	$ 0	$ 0	$ 0	$ 0
Cost and expenses:
Depreciation	6,543	2,848	13,274	9,090
Research and development	2,737,028	1,526,277	4,597,864	3,695,420
General and administrative	2,431,499	2,458,097	6,287,295	6,774,407
Total costs and expenses	5,175,070	3,987,222	10,898,433	10,478,917
Operating loss	(5,175,070)	(3,987,222)	(10,898,433)	(10,478,917)
Interest income	5,744	1,104	6,623	3,086
Net loss	$ (5,169,326)	$ (3,986,118)	$ (10,891,810)	$ (10,475,831)
Net loss per share—basic and diluted (in dollars per share)	$ (0.11)	$ (0.08)	$ (0.23)	$ (0.23)
Weighted average number of common shares— basic and diluted (in shares)	47,893,404	47,372,490	47,892,919	46,464,343

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance	$ 43,118	$ 89,295,601	$ (58,422,229)	$ 30,916,490
Balance (in shares) at Dec. 31, 2020	43,117,681
Balance at Dec. 31, 2020	$ 43,118	89,295,601	(58,422,229)	30,916,490
Issuance of stock for cash (in shares)	4,192,139
Issuance of stock for cash	$ 4,192	25,320,138	0	25,324,330
Issuance of stock for services (in shares)	5,000
Issuance of stock for services	$ 5	20,645	0	20,650
Share based compensation	0	651,088	0	651,088
Net loss	$ 0	0	(6,489,714)	(6,489,714)
Balance (in shares) at Mar. 31, 2021	47,314,820
Balance at Mar. 31, 2021	$ 47,315	115,287,472	(64,911,942)	50,422,845
Balance (in shares) at Dec. 31, 2020	43,117,681
Balance at Dec. 31, 2020	$ 43,118	89,295,601	(58,422,229)	30,916,490
Net loss				(10,475,831)
Balance (in shares) at Jun. 30, 2021	47,522,857
Balance at Jun. 30, 2021	$ 47,523	116,534,756	(68,898,060)	47,684,218
Balance (in shares) at Dec. 31, 2020	43,117,681
Balance at Dec. 31, 2020	$ 43,118	89,295,601	(58,422,229)	$ 30,916,490
Issuance of stock for services (in shares)				86,138
Issuance of stock for services				$ 156,045
Balance (in shares) at Dec. 31, 2021	47,874,708
Balance at Dec. 31, 2021	$ 47,874	119,246,970	(78,017,853)	41,276,991
Balance	$ 47,315	115,287,472	(64,911,942)	50,422,845
Balance (in shares) at Mar. 31, 2021	47,314,820
Balance at Mar. 31, 2021	$ 47,315	115,287,472	(64,911,942)	50,422,845
Issuance of stock for cash (in shares)	203,037
Issuance of stock for cash	$ 203	109,830	0	110,033
Issuance of stock for services (in shares)	5,000
Issuance of stock for services	$ 5	21,095	0	21,100
Share based compensation	0	1,116,359	0	1,116,358
Net loss	$ 0	0	(3,986,118)	(3,986,118)
Balance (in shares) at Jun. 30, 2021	47,522,857
Balance at Jun. 30, 2021	$ 47,523	116,534,756	(68,898,060)	47,684,218
Balance	47,523	116,534,756	(68,898,060)	47,684,218
Balance	$ 47,874	119,246,970	(78,017,853)	41,276,991
Balance (in shares) at Dec. 31, 2021	47,874,708
Balance at Dec. 31, 2021	$ 47,874	119,246,970	(78,017,853)	41,276,991
Issuance of stock for services (in shares)	5,000
Issuance of stock for services	$ 5	17,495	0	17,500
Share based compensation	0	1,452,607	0	1,452,607
Net loss	$ 0	0	(5,722,484)	(5,722,484)
Balance (in shares) at Mar. 31, 2022	47,879,708
Balance at Mar. 31, 2022	$ 47,879	120,717,072	(83,740,337)	37,024,614
Balance (in shares) at Dec. 31, 2021	47,874,708
Balance at Dec. 31, 2021	$ 47,874	119,246,970	(78,017,853)	$ 41,276,991
Issuance of stock for services (in shares)				10,000
Issuance of stock for services				$ 28,650
Net loss				(10,891,810)
Balance (in shares) at Jun. 30, 2022	47,898,351
Balance at Jun. 30, 2022	$ 47,898	121,273,050	(88,909,663)	32,411,285
Balance	$ 47,879	120,717,072	(83,740,337)	37,024,614
Balance (in shares) at Mar. 31, 2022	47,879,708
Balance at Mar. 31, 2022	$ 47,879	120,717,072	(83,740,337)	37,024,614
Issuance of stock for services (in shares)	18,643
Issuance of stock for services	$ 19	17,953	0	17,972
Share based compensation	0	538,026	0	538,026
Net loss	$ 0	0	(5,169,326)	(5,169,326)
Balance (in shares) at Jun. 30, 2022	47,898,351
Balance at Jun. 30, 2022	$ 47,898	121,273,050	(88,909,663)	32,411,285
Balance	$ 47,898	$ 121,273,050	$ (88,909,663)	$ 32,411,285

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (10,891,810)	$ (10,475,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	13,274	9,090
Share based compensation	2,026,104	1,809,196
Changes in operating assets and liabilities:
Prepaid expenses and other	(337,762)	(371,043)
Accounts payable	(289,872)	176,824
Other current liabilities	858,415	419,671
Net cash used in operating activities	(8,621,651)	(8,432,093)
Cash flows from investing activities:
Additions to property and equipment	0	(9,142)
Additions to intellectual property	(23,689)	(18,048)
Reductions (additions) to research and development supplies	69,485	(51,315)
Net cash provided (used) by investing activities	45,796	(78,505)
Cash flows from financing activities:
Proceeds from issuances of stock	0	25,434,363
Net cash provided by financing activities	0	25,434,363
Net (decrease) increase in cash and cash equivalents	(8,575,855)	16,923,765
Cash and cash equivalents, beginning of period	38,628,876	27,319,684
Cash and cash equivalents, end of period	$ 30,053,021	$ 44,243,449

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our non-viral ONCOPREX™ Nanoparticle Delivery System. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our diabetes technology is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. Oncology Platform Our lead oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX- 001, TUSC2. not We currently are enrolling and treating patients in two 1/2 1 2 1 1" August 2022, 1 second 0.09 0.06 first 1 1 2022. 2 2” first 2 April 2022. 1 2 2023. two one We expect to initiate a clinical trial in SCLC by year end 2022 The TUSC2 one Diabetes Gene Therapy In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) for the treatment of Type 1 2 Pdx1 August 2022, 2 Capital Requirements, Liquidity and Going Concern Considerations Our unaudited condensed financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying unaudited condensed financial statements, we have sustained substantial losses from operations since inception and have no Management recognizes that we must obtain additional capital resources to successfully commercialize our product candidates. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no not may not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP. However, they do not not six June 30, 2022 not may December 31, 2022 December 31, 2021 10 March 30, 2022. Capital Stock The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share. Use of Estimates The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We consider all highly liquid short-term investments with an initial maturity of three $250,000 June 30, 2022 December 31, 2021 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Level 2: not Level 3: Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 Research and development supplies purchased and capitalized for future use were $2,952,917 and $3,022,403 at June 30, 2022 December 31, 2021 Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not six June 30, 2022 December 31, 2021 no Recent Accounting Developments Accounting pronouncements issued but not June 30, 2022 not

Note 3 - Intellectual Property

Note 3 - Intellectual Property	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3 On February 11, 2020, 1 2 On May 4, 2020, 16 We own or have exclusive license agreements on 18 18

Note 4 - Equity

Note 4 - Equity	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 4 Registered Direct Offerings On February 10, 2021, Stock Issuances During the six June 30, 2022 During the year ended December 31, 2021 Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, none June 30, 2022 Common Stock The Company is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 47,898,351 shares of the Company's common stock outstanding at June 30, 2022 Common Stock Purchase Warrants Common stock purchase warrant activity for the period and year ended June 30, 2022 December 31, 2021 Number of Weighted Average Warrants Exercise Price Outstanding at January 1, 2021 2,154,747 $ 4.37 Issued 50,000 5.29 Outstanding at December 31, 2021 2,204,747 $ 4.39 Cancelled or expired 112,993 4.47 Exercised 13,643 0.50 Outstanding at June 30, 2022 2,078,111 $ 4.41 Vested or expected to vest at June 30, 2022 — — Exercisable at June 30, 2022 1,844,776 $ 4.66 The Company did not six June 30, 2022 In the year ended December 31, 2021, December 31, 2021, On January 29, 2018, June 30, 2022 not 2018 The Company’s board of directors and stockholders have approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 422 1986, may may A total of 4,160,000 shares of common stock were initially available under the 2018 not 2009 “2009 No 2009 In addition, the number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019, December 31 2018 On January 1, 2021, 2022, 2018 June 30, 2022 2018 2018 The Company’s board of directors and stockholders approved and adopted the Company’s 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not January 1, 2022 Stock Options As of June 30, 2022 ten Expected term (in years): 10 Risk-free rate: 0.07% – 2.79% Volatility: 75.98% – 88.38% Dividend yield: 0% During the six June 30, 2022 In the year ended December 31, 2021, The weighted average remaining contractual term for the outstanding options at June 30, 2022 December 31, 2021 Stock option activity for the six June 30, 2022 December 31, 2021 Number of Weighted Average Shares Exercise Price Outstanding at January 1, 2021 6,844,069 $ 2.81 Options granted 2,519,628 4.26 Options exercised (670,889 ) 1.01 Options expired (118,507 ) 3.00 Outstanding at December 31, 2021 8,574,301 $ 3.35 Options granted 2,892,166 2.18 Options expired or cancelled (17,500 ) 2.00 Outstanding at June 30, 2022 11,448,967 $ 3.06 Vested or expected to vest at June 30, 2022 235,465 3.32 Exercisable at June 30, 2022 6,166,620 $ 3.20 Share-Based Compensation For the six June 30, 2022 June 30, 2022 not three June 30, 2022 As of June 30, 2022 not may

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 5 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board of which Mr. Varner is the sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In April 2009, August 2012, 2011

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6 Leases On April 16, 2018, March 23, 2021, not April 30, 2021, 19 Commitments MD Anderson Cancer Center The Company entered into a clinical study agreement with MD Anderson, to administer the Company’s Phase 1/2 4 2018 may 2020, 1 no 002 June 2021, 1 In July 2018, two may May 2022. In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five National Institutes of Health Our $191,393 payment obligation to the National Institutes of Health (“NIH”) represented a current obligation, of which $15,393 of 2016 fourth 2016 December 31, 2016 ( first 2017, 2018, second 2017. As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000 $240,000 first 2017. $240,000 $20,000 June 30, 2022 University of Pittsburgh Pursuant to the Exclusive License Agreement dated February 11, 2020 first three first first 20 first Contingencies From time to time, we may not

Note 7 - Significant Events

Note 7 - Significant Events	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Effect of Covid 19 Pandemic [Text Block]	Note 7 The COVID- 19 may March 31, 2021, not 19 June 2021, 19

Note 8 - Subsequent Events

Note 8 - Subsequent Events	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 Share Issuance On July 1, 2022, Warrant Issuances On July 1, 2022, August 10, 2022, Option Exercise On July 28, 2022, Option Issuance On August 10, 2022, 2018

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Stockholders' Equity, Policy [Policy Text Block]	Capital Stock The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid short-term investments with an initial maturity of three $250,000 June 30, 2022 December 31, 2021
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Level 2: not Level 3:
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 Research and development supplies purchased and capitalized for future use were $2,952,917 and $3,022,403 at June 30, 2022 December 31, 2021
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not six June 30, 2022 December 31, 2021 no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments Accounting pronouncements issued but not June 30, 2022 not

Note 4 - Equity (Tables)

Note 4 - Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Weighted Average Warrants Exercise Price Outstanding at January 1, 2021 2,154,747 $ 4.37 Issued 50,000 5.29 Outstanding at December 31, 2021 2,204,747 $ 4.39 Cancelled or expired 112,993 4.47 Exercised 13,643 0.50 Outstanding at June 30, 2022 2,078,111 $ 4.41 Vested or expected to vest at June 30, 2022 — — Exercisable at June 30, 2022 1,844,776 $ 4.66
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected term (in years): 10 Risk-free rate: 0.07% – 2.79% Volatility: 75.98% – 88.38% Dividend yield: 0%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Average Shares Exercise Price Outstanding at January 1, 2021 6,844,069 $ 2.81 Options granted 2,519,628 4.26 Options exercised (670,889 ) 1.01 Options expired (118,507 ) 3.00 Outstanding at December 31, 2021 8,574,301 $ 3.35 Options granted 2,892,166 2.18 Options expired or cancelled (17,500 ) 2.00 Outstanding at June 30, 2022 11,448,967 $ 3.06 Vested or expected to vest at June 30, 2022 235,465 3.32 Exercisable at June 30, 2022 6,166,620 $ 3.20

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Apr. 03, 2018	Mar. 31, 2018
Capital Stock, Shares Authorized (in shares)				210,000,000
Common Stock, Shares Authorized (in shares)	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01	$ 0.001	$ 0.001
Cash, Uninsured Amount	$ 29,757,127	$ 38,392,886
Research and Development Assets, Current	$ 2,952,917	$ 3,022,403
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years

Note 4 - Equity (Details Textua

Note 4 - Equity (Details Textual) - USD ($)				3 Months Ended				6 Months Ended		12 Months Ended
	Jan. 01, 2022	Feb. 10, 2021	Jan. 01, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Apr. 03, 2018	Mar. 31, 2018	Jan. 29, 2018
Proceeds from Issuance of Common Stock								$ 0	$ 25,434,363
Stock Issued During Period, Shares, Issued for Services (in shares)								10,000		86,138
Stock Issued During Period, Value, Issued for Services				$ 17,972	$ 17,500	$ 21,100	$ 20,650	$ 28,650		$ 156,045
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)								13,643
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)										670,889
Stock Issued During Period, Value, Stock Options Exercised										$ 677,912
Preferred Stock, Shares Authorized (in shares)				10,000,000				10,000,000		10,000,000		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.01				$ 0.01		$ 0.01		$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0				0		0
Common Stock, Shares Authorized (in shares)				200,000,000				200,000,000		200,000,000		200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001				$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common Stock, Shares, Outstanding, Ending Balance (in shares)				47,898,351				47,898,351		47,874,708
Class of Warrant or Right, Issued in Period (in shares)								0		50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 4.41				$ 4.41		$ 4.39	$ 4.37
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				11,448,967				11,448,967		8,574,301	6,844,069
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 3.06				$ 3.06		$ 3.35	$ 2.81
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								2,892,166		2,519,628
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)								$ 2.18		$ 4.26
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)								17,500		118,507
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)								$ 2		$ 3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)								7 years 5 months 23 days		7 years 2 months 26 days
Class of Warrant or Right, Outstanding (in shares)				2,078,111				2,078,111		2,204,747	2,154,747
Share-Based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense								$ 2.1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 10,600,000				$ 10,600,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								2 years 3 months 14 days
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				0				0
Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)										$ 0.015
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)								12 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 0.015				$ 0.015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)								0.015
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)								$ 1.36		2.72
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)										1.45
Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)										2.15
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)								48 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 9.80				$ 9.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)								7.93
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)								$ 3.50		7.22
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)										$ 7.22
The 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)				145,816				145,816				4,160,000
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year												5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	2,393,735		2,155,884
The 2009 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)												2,628,749
The 2018 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year												2%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)												208,500
Bear Creek Capital Warrant One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 7.22
Bear Creek Capital Warrant Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 3.36
Bear Creek Capital Warrants [Member]
Share-based Payment Arrangement, Expense										$ 200,282
Performance-based Warrant [Member]
Class of Warrant or Right, Outstanding (in shares)				1				1
Warrant, Nonvested Award, Cost Not yet Recognized, Amount				$ 300,000				$ 300,000
FundAthena, Inc [Member] | Warrants Issued for Services [Member]
Class of Warrant or Right, Issued in Period (in shares)								0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 5
Accounts Payable, Total														$ 30,000
Registered Direct Offering [Member] | Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,000,000
Shares Issued, Price Per Share (in dollars per share)		$ 6.25
Proceeds from Issuance of Common Stock		$ 23,200,000

Note 4 - Equity - Common Stock

Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Outstanding, number of warrants (in shares)	2,204,747	2,154,747
Outstanding, weighted average exercise price (in dollars per share)	$ 4.39	$ 4.37
Issued, number of warrants (in shares)	0	50,000
Issued, weighted average exercise price (in dollars per share)		$ 5.29
Cancelled or expired, number of warrants (in shares)		112,993
Cancelled or expired, weighted average exercise price (in dollars per share)		$ 4.47
Exercised, number of warrants (in shares)		13,643
Exercised, weighted average exercise price (in dollars per share)		$ 0.50
Outstanding, number of warrants (in shares)	2,078,111	2,204,747
Outstanding, weighted average exercise price (in dollars per share)	$ 4.41	$ 4.39
Vested or expected to vest, number of warrants (in shares)	0
Vested or expected to vest, weighted average exercise price (in dollars per share)	$ 0
Exercisable, number of warrants (in shares)	1,844,776
Exercisable, weighted average exercise price (in dollars per share)	$ 4.66

Note 4 - Equity - Assumptions (

Note 4 - Equity - Assumptions (Details)	6 Months Ended
	Jun. 30, 2022
Expected term (in years): (Year)	10 years
Dividend yield:	0%
Minimum [Member]
Risk-free rate:	0.07%
Volatility:	75.98%
Maximum [Member]
Risk-free rate:	2.79%
Volatility:	88.38%

Note 4 - Equity - Stock Option

Note 4 - Equity - Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Outstanding, number of shares (in shares)	8,574,301	6,844,069
Outstanding, weighted average exercise price (in dollars per share)	$ 3.35	$ 2.81
Options granted, number of shares (in shares)	2,892,166	2,519,628
Options granted, weighted average exercise price (in dollars per share)	$ 2.18	$ 4.26
Options exercised, number of shares (in shares)		(670,889)
Options exercised, weighted average exercise price (in dollars per share)		$ 1.01
Options expired (in shares)	(17,500)	(118,507)
Options expired, weighted average exercise price (in dollars per share)	$ 2	$ 3
Outstanding, number of shares (in shares)	11,448,967	8,574,301
Outstanding, weighted average exercise price (in dollars per share)	$ 3.06	$ 3.35
Vested or expected to vest, number of shares (in shares)	235,465
Vested or expected to vest, weighted average exercise price (in dollars per share)	$ 3.32
Exercisable, number of shares (in shares)	6,166,620
Exercisable, weighted average exercise price (in dollars per share)	$ 3.20

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 31, 2018

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Jun. 30, 2022

Jun. 30, 2021

Dec. 31, 2018

Dec. 31, 2016

Dec. 31, 2009

Mar. 31, 2022

Mar. 03, 2021

Feb. 11, 2020

Other Commitment, Total

$ 340,000

Payments to Acquire Intangible Assets

$ 23,689

$ 18,048

License Agreement Terms [Member]

License Agreement Milestone Payment

$ 6,150,000

National Institute of Health [Member]

Royalty on Sales, Percentage

1%

Royalty Term (Year)

21 years

Royalty Payment, Annual Minimum

$ 20,000

Other Commitment, Total

$ 191,393

$ 191,393

Legal Fees

15,393

Accounts Payable, Other, Current

176,000

176,000

Accrued Royalties, Current

$ 140,000

140,000

Other Expenses, Total

$ 36,000

Extinguishment of Debt, Amount

$ 120,000

Accrued Patent Costs, Current

36,000

Payments for Royalties

$ 20,000

20,000

Payment for Contingent Consideration Liability, Operating Activities

240,000

Contingent Payments Annual Increase

20,000

Payments to Acquire Intangible Assets

$ 36,000

Finite-Lived Intangible Assets, Period Increase (Decrease), Total

$ (120,000)

Clinical Trial Agreement [Member] | MD Anderson [Member]

Long Term Contract, Estimated Cost

$ 2,000,000

Research Agreement [Member] | MD Anderson [Member]

Long Term Contract, Estimated Cost

$ 2,000,000

License Agreement [Member] | University of Pittsburgh [Member]

Licensing Fee, Amount

$ 25,000

Annual Maintenance Fee, First Three Years, Amount

25,000

Annual Maintenance Fee, After Year Three, Amount

40,000

Annual Royalty Payment Per Year, Minimum

$ 250,000

Share of Non-Royalty Sublicense Income, Percent

20%

License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member]

Milestone Payment

$ 3,975,000

License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member]

Royalty Percent, Licensed Technology Covered by Patent

1.50%

License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member]

Royalty Percent, Licensed Technology Covered by Patent

3%

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)				6 Months Ended		12 Months Ended
	Aug. 10, 2022	Jul. 28, 2022	Jul. 01, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Stock Issued During Period, Shares, Issued for Services (in shares)				10,000		86,138
Class of Warrant or Right, Issued in Period (in shares)				0		50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 4.41		$ 4.39	$ 4.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)						670,889
Proceeds from Issuance of Common Stock				$ 0	$ 25,434,363
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				2,892,166		2,519,628
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)				$ 3.20
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)			5,000
Class of Warrant or Right, Issued in Period (in shares)	50,000		50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.49		$ 1.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		116,953
Proceeds from Issuance of Common Stock		$ 1,755
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	9,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.49